Breast cancer, with around 2 million new cases in 2019, is the second most common cancer
worldwide and the second leading cause of cancer death among females. The aim of this …

Although breakthroughs in cancer treatment have been achieved, immunotherapy yields
only modest benefits in most patients. There is still a gap in clarifying the immune …

Tumorigenesis has long been linked to the evasion of the immune system and the
uncontrolled proliferation of transformed cells. The complement system, a major arm of …

Melanoma originates from melanin-producing cells called melanocytes. Melanoma poses a
great risk because of its rapid ability to spread and invade new organs. Cellular metastasis …

Mesothelioma is an aggressive cancer of the serous membranes with poor prognosis
despite combination therapy consisting of surgery, radiotherapy, and platinum-based …

Understanding at the molecular level of the cell biology of tumors has led to significant
treatment advances in the past. Despite such advances however, development of therapy …

Complement component C1q can act as a pro-tumorigenic factor in the tumor
microenvironment (TME). The TME in malignant pleural mesothelioma (MPM) is rich in C1q …

Immunodeficiencies are widely becoming known as important features of multiple myeloma
(MM) and may promote the proliferation of malignant cells as well as confer resistance to …

Abstract Hyaluronan‑binding protein 1 (HABP1) is among the molecules known to bind to
hyaluronan and is involved in a variety of cellular processes, including cell proliferation and …

Abstract Background: Hyaluronan-binding protein 1 (HABP1) is one of molecules that binds
to hyaluronan and is involved in a variety of cellular processes including cell proliferation …